SHANGHAI, April 3 (Reuters) - A drugmaker in China has developed a biosimilar version of Novo Nordisk's , opens new tab popular diabetes drug Ozempic and applied for approval to sell it there, in ...

Novo Nordisk said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where it estimates more than 180 million people live with ...

China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend isn’t confined to Big Tech: it has been quietly happening in the ...

Ivonescimab, the new drug, was found in a trial conducted in China to have bested Keytruda, the blockbuster medication developed by Merck that has raked in more than $130 billion in sales for the ...

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with ...

China’s National Medical Products Administration (NMPA) has approved four new drugs developed by local biopharma companies, including a first-of-its-kind molecule in blood cancer. Wednesday ...

Akeso’s new drug, which is not a generic, has been approved by China’s pharmaceutical regulator for some lung cancer patients. But it is still years away from being sold in the US.